Exelgen forms partnership with leading biotech firms
Exelgen Ltd (formerly Tripos Discovery Research), a subsidiary of Commonwealth Biotechnologies, Inc and provider of drug discovery chemistry services, has formed new collaborations with two prominent European-based biotechnology companies.
Exelgen Ltd (formerly Tripos Discovery Research), a subsidiary of Commonwealth Biotechnologies, Inc and provider of drug discovery chemistry services, has formed new collaborations with two prominent European-based biotechnology companies.
Because of the proprietary nature of the collaborations both companies have declined to be identified or disclose the contract values at this time. One company is a long-standing client, the other a new client.
Drawing upon Exelgen's proprietary knowledge-driven chemistry process, the partnerships encompass a range of collaborative research activities including medicinal chemistry and application of Exelgen's LeadHopping technology to identify and progress lead compound series into preclinical studies.
Mark Warne, MD of Exelgen said: "As we enter 2008, we are committed to expanding our capabilities to provide clients an integrated drug discovery platform from hit identification up through IND enabling studies. We are currently engaged in more high value discovery research programs than ever before, and we look forward to generating excellent results for our clients."
Exelgen offers compound libraries under the LeadQuest brand, screening libraries under the LeadScreen brand and custom de novo compound libraries under the LeadSelect brand. It has won several new contracts with major pharmaceutical clients, such as Schering Plough and Elan.
